Inspiration Healthcare Group PLC · LSE:IHC

Inspiration Healthcare — Investor Presentation (January 2017)

23 slides from Inspiration Healthcare's investor presentation, Jan 31, 2017

  1. Slide 1: Inspiration Healthcare Group plc Investor Presentation

    Inspiration Healthcare Group plc Investor Presentation Year ending 31 January 2017

  2. Slide 2: Disclaimer

    DISCLAIMER • While the information contained herein has been prepared by Inspiration Healthcare Group plc (“Inspiration”) in good faith, neither it nor any of its directors, officers, agents, advisers, affiliates or employees makes any representation or warranty, express or implied, nor shall any of

  3. Slide 3: Our Business

    Our Business Our vision • To improve patient outcomes in critical care. Our mission • To develop outcome-enhancing products for intensive care patients and to promote these globally. We are passionate about improving patient outcomes through innovation, research and life-saving customer service. The

  4. Slide 4: Babies in the UK born prematurely

    • Insert WOW photo/image here 1 in 9 babies in the UK are born prematurely. 3

  5. Slide 5: 10% of babies required assistance to breathe at birth

    10% of babies required assistance to breathe at birth. 4 4

  6. Slide 6: Cost of a day of neonatal intensive care

    It costs up to £1,311 for a baby to be cared for in intensive care for one day. 5

  7. Slide 7: Our Strategy and Market

    Our Strategy and Market Market Focus - Neonatal Intensive Care and Operating Theatre Target Market Today1 • Perinatal Healthcare – improving outcomes worldwide Critical Care • Surgery drive for cost effective outcome improvement Inspiration Branded • Middle-High income countries where premiums are p

  8. Slide 8: 2017 Highlights

    2017 Highlights Financial Highlights • Revenues up 9.4% to £14.3m (2016: £13.1m) 1 • Gross margin percentage decreased to 44.4% (2016: 45.6%) 1 - FX impact on Distributed Products • Operating Profit £1.2m (2016: £1.1m) 1, 2 • Adjusted Earnings Per Share 3.4p (2016: 3.4p) 1 , 2 • Net cash £2.2m Opera

  9. Slide 9: Consolidated Income Statement

    Consolidated Income Statement Audited Unaudited 12 months 12 months to 2017 to 2016 Actual Proforma £’000 £’000 Revenue 14,323 13,096 Operating profit 1 1,163 1,109 Exceptional items and Impairment of Intangible assets (718) (1,389) Finance (Expense)/Income (1) 3 Profit/(Loss) before tax 444 (276) T

  10. Slide 10: Exceptional Items

    Exceptional Items 12 months 12 months 2017 2016 Actual Proforma £’000 £’000 Closure of Rotherham and Related Costs 645 - Severance costs (2017: CFO) 135 170 Exceptional Items related to Reverse Acquisition (62) 701 Impairment of goodwill and intangible assets - 517 Total Charge 718 1,388 9

  11. Slide 11: Consolidated Balance Sheet

    Consolidated Balance Sheet 31 January 31 January 2017 2016 £’000 £’000 Non-Current Assets 1,006 553 Cash 2,165 2,319 Other Current Assets 3,269 2,927 Total Liabilities (3,315) (2,986) Net Assets 3,125 2,813 Total Equity attributable to the owners of the parent company 3,125 2,813 10

  12. Slide 12: Revenue by Product Ownership 2017

    Revenue by Product Ownership 2017 Technical Support 12% Other Inspiration 2% Branded 45% Distributed 41% Margin Analysis Operating Product Ownership Critical Care Home Healthcare Theatre Inspiration Branded e.g. Inspire CPAP, Tecotherm, 35 – 70% 50 – 70% n/a Unique CFM, Inspire rPAP, Alpha Distribut

  13. Slide 13: Revenue by Market Segment

    Revenue by Market Segment Critical Care £10.0M Operating Theatre Thermoregulation Respiratory £1.9M Brain Monitoring Thermoregulation Acutronic Medos Novalung Acutronic 13% 70% 17% Home Healthcare £2.4M Parenteral Feeding Industrial Temp Control 12

  14. Slide 14: Recurring Revenue

    Recurring Revenue 2017 2016 Other Other 1% 1% Service Service Capital 12% 12% Capital 33% 38% Consumables 54% Consumables 49% 13

  15. Slide 15: Geographic Breakdown

    Geographic Breakdown Sales 2017 Sales 2016 ME&A Americas Asia Pac 7% ME&A Americas 3% Asia Pac 7% 5% 3% 3% Europe 16% Europe 14% Domestic Domestic 71% 71% 14

  16. Slide 16: Business Environment

    Business Environment Short Term • Post Brexit Vote: - Initial business slowdown: in UK NHS especially capital - recovered by year end - Currency Volatility • Regulatory - Greater scrutiny of Quality Management Systems - More stringent appraisal of new products Long Term • No evidence around the worl

  17. Slide 17: Acquisition Targets

    Acquisition Targets Neonatal Intensive Care -Thermo-regulation Operation Theatre - Respiratory Support - Thermo-regulation - Resuscitation Neonatal Intensive Care Operating Theatre - Jaundice Management - Anaesthesia - Positioning / Developmental - Monitoring - Neurological Neonatal Intensive Care O

  18. Slide 18: Priorities and Outlook

    Priorities and Outlook Priorities • Continue organic growth through current products • Increase R&D focus and investment in FY to enhance revenue growth in future years • New product launches planned for 2017: – rPAP Driver delayed from 2016 due to regulatory process – Tecotherm Helix – Alpha contro

  19. Slide 19: Appendices

    Appendices

  20. Slide 20: Consolidated Income Statement (statutory)

    Consolidated Income Statement (statutory) Note that the 2016 income statement represents 12 months of Inspiration Healthcare Ltd and 7 months of Inditherm plc from the reverse takeover date (24 June 2015) 12 months 12 months 2017 2016 Revenue 14,323 12,279 Operating profit (before exceptional items

  21. Slide 21: Consolidated Cash Flow

    Consolidated Cash Flow 12 months 12 months 2017 2016 Profit before taxation 444 148 Impairment of goodwill and intangible assets - 517 Decrease in trade and other receivables (461) 379 Increase in trade and other payables 598 579 Other (17) (3) Net cash inflow from operating activities 564 1,620 Cas

  22. Slide 22: Shareholder Base

    Shareholder Base Institutional Shareholders 28% Management Shareholders 50% Notifiable Private Investors 10% Other/ Free Float 12% 21

  23. Slide 23: The Inspiration Story

    The Inspiration Story 2017 2016 Sales c.£14.3 m* Sales c.£13.1m* 2015 Sales c.£9.5m 2014 Sales c.£8.8m 2010 Sales c.£5.3m Acquired Outsource Inditherm and Manufacturing 2007 Further Investment prepare to Reengineered Sales c.£1.6m in R&D launch own Company Launched Inspire products 2003 nCPAP Sales

Inspiration Healthcare Group — Investor Presentation (January 2017) on 6ix